Header Logo

Connection

RACHELLE DOODY to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications RACHELLE DOODY has written about Antibodies, Monoclonal, Humanized.
RACHELLE DOODY
Connection Strength
3.534
Antibodies, Monoclonal, Humanized
  1. Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurol. 2025 Jan 01; 82(1):19-29.
    View in: PubMed
    Score: 0.426
  2. At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact. J Prev Alzheimers Dis. 2024; 11(3):537-548.
    View in: PubMed
    Score: 0.397
  3. Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD). J Alzheimers Dis. 2024; 101(1):353-367.
    View in: PubMed
    Score: 0.397
  4. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. JAMA Neurol. 2022 11 01; 79(11):1113-1121.
    View in: PubMed
    Score: 0.366
  5. Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab. J Prev Alzheimers Dis. 2021; 8(1):3-6.
    View in: PubMed
    Score: 0.323
  6. Editorial: Consequences of the FDA Decision on Aducanumab for Patient Care and Research. J Prev Alzheimers Dis. 2021; 8(4):393-395.
    View in: PubMed
    Score: 0.323
  7. Gantenerumab reduces amyloid-? plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis. Alzheimers Res Ther. 2019 12 12; 11(1):101.
    View in: PubMed
    Score: 0.300
  8. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med. 2014 04 10; 370(15):1460.
    View in: PubMed
    Score: 0.202
  9. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):311-21.
    View in: PubMed
    Score: 0.199
  10. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. N Engl J Med. 2023 Nov 16; 389(20):1862-1876.
    View in: PubMed
    Score: 0.098
  11. Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med. 2022 08 04; 387(5):421-432.
    View in: PubMed
    Score: 0.090
  12. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med. 2021 Jul; 27(7):1187-1196.
    View in: PubMed
    Score: 0.083
  13. Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force. J Prev Alzheimers Dis. 2021; 8(3):306-312.
    View in: PubMed
    Score: 0.081
  14. The Future of Anti-Amyloid Trials. J Prev Alzheimers Dis. 2020; 7(3):146-151.
    View in: PubMed
    Score: 0.075
  15. What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force. J Prev Alzheimers Dis. 2018; 5(3):171-174.
    View in: PubMed
    Score: 0.065
  16. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44.
    View in: PubMed
    Score: 0.048
  17. Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024 Dec; 30(12):3669-3675.
    View in: PubMed
    Score: 0.026
  18. Gantenerumab in Early Alzheimer's Disease. Reply. N Engl J Med. 2024 Feb 29; 390(9):867.
    View in: PubMed
    Score: 0.025
  19. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009 Dec 15; 73(24):2061-70.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.